(Hypertension. 1999;33:130-136.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Mechanisms of FK 506–Induced Hypertension in the Rat
From the Second Department of Internal Medicine (Y.T., K.F., H.M.), Department of Health Sciences (Y.T.), School of Medicine, Kanazawa University, Kanazawa, Japan; and the Third Department of Internal Medicine (I.M., S.I.), Fukui Medical School, Fukui, Japan.
Correspondence to Yoshiyu Takeda, MD, Second Department of Internal Medicine, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920, Japan.
Abstract—Tacrolimus (FK 506) is a powerful, widely used immunosuppressant. The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity. To clarify the mechanisms of FK 506–induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels. In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506–induced hypertension in rats was studied. FK 506, 5 mg · kg-1 · d-1 given for 4 weeks, elevated blood pressure from 102±13 to 152±15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively). Little change was observed in the expression of ECE-1 mRNA and CNP mRNA. FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively). The administration of FR 139317 (10 mg · kg-1 · d-1) prevented FK 506–induced hypertension in rats. These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.
Key Words: FK 506 • endothelin receptor antagonist • endothelin • nitric oxide • hypertension • endothelin-converting enzyme • natriuretic peptides
This article has been cited by other articles:
 |
|
 |
|
  T. L. Thai, S. K. Fellner, and W. J. Arendshorst ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1107 - F1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Long, L. G. Cook, G.-Y. Wu, and B. M. Mitchell Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Long, L. G. Cook, S. L. Hamilton, G.-Y. Wu, and B. M. Mitchell FK506 Binding Protein 12/12.6 Depletion Increases Endothelial Nitric Oxide Synthase Threonine 495 Phosphorylation and Blood Pressure Hypertension, March 1, 2007; 49(3): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Krotz, M. Keller, S. Derflinger, H. Schmid, T. Gloe, F. Bassermann, J. Duyster, C. D. Cohen, C. Schuhmann, V. Klauss, et al. Mycophenolate Acid Inhibits Endothelial NAD(P)H Oxidase Activity and Superoxide Formation by a Rac1-Dependent Mechanism Hypertension, January 1, 2007; 49(1): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Di Filippo, F. Rossi, E. Ongini, P. Del Soldato, M. Perretti, and M. D'Amico The Distinct Alterations Produced in Cardiovascular Functions by Prednisolone and Nitro-prednisolone (NCX-1015) in the Rat Highlight a Causal Role for Endothelin-1 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1133 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy Cardiovasc Res, February 1, 2002; 53(2): 294 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]
|
|